Enhanced activity of doxorubicin in drug resistant A549 tumor cells by encapsulation of P-glycoprotein inhibitor in PLGA-based nanovectors

Oncology Letters

Volumn 7, Issue 2, 2014, Pages 387-392

  Xu, Liang ^a   Li, Hua ^b   Wang, Yubin ^b   Dong, Fang ^a   Wang, Huangbing ^a   Zhang, Shutong ^c  

^a TONGREN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Wuhan University of Science and Technology ^*  (China)

Author keywords

Drug resistance; Efflux pump; P glycoprotein; Poly(D,L lactide co glycolide) nanoparticles

Indexed keywords

DOXORUBICIN; NANOCARRIER; POLY(DEXTRO LACTIDE CO GLYCOLIDE); UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG UPTAKE; ELECTRON MICROSCOPY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; MOUSE; NANOENCAPSULATION; NONHUMAN; SURVIVAL RATE; TUMOR CELL; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84890355236     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1711     Document Type: Article

References (26)

1. Schimrosczyk K, Song YH, Vykoukal J, et al: Liposome-mediated transfection with extract from neonatal rat cardiomyocytes induces transdifferentiation of human adipose-derived stem cells into cardiomyocytes. Scand J Clin Lab Invest68: 464-472, 2008.
2. Villanueva J, Infante JR, Krepler C, et al: Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep 4:1090-1099, 2013.
3. Niu C, Sun Q, Zhou J, et al: Folate-functionalized polymeric micelles based on biodegradable PEG-PDLLA as a hepatic carcinoma-targeting delivery system. Asian Pac J Cancer Prev12: 1995-1999, 2011.
4. Dreaden EC, Austin LA, Mackey MA and El-Sayed MA: Size matters: gold nanoparticles in targeted cancer drug delivery. Ther Deliv3: 457-478, 2012.
5. Parhi P, Mohanty C and Sahoo SK: Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today17: 1044-1052, 2012.
6. Shive MS and Anderson JM: Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev28: 5-24, 1997.
7. Makadia HK and Siegel SJ: Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel) 3: 1377-1397, 2011.
8. Ullah MF: Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev9: 1-6, 2008.
9. Pluchino KM, Hall MD, Goldsborough AS, et al: Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat15: 98-105, 2012.
10. Zhang L, Xiao R, Xiong J, et al: Activated ERM protein plays a critical role in drug resistance of MOLT4 cells induced by CCL25. PLoS One8: e52384, 2013.
11. Larsen UL, Hyldahl Olesen L, Guldborg Nyvold C, et al: Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest67: 123-134, 2007.
12. Han M, Lv Q, Tang XJ, et al: Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. J Control Release163: 136-144, 2012.
13. Nieto Montesinos R, Béduneau A, Pellequer Y and Lamprecht A: Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes. J Control Release161: 50-61, 2012.
14. Shen F, Chu S, Bence AK, et al: Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther324: 95-102, 2008.
15. Liu R, Zhang Y, Chen Y, et al: A novel calmodulin antagonist O-(4-ethoxyl-butyl)-berbamine overcomes multidrug resistance in drug-resistant MCF-7/ADR breast carcinoma cells. J Pharm Sci99: 3266-3275, 2010.
16. Harmsen S, Meijerman I, Febus CL, et al: PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol66: 765-771, 2010.
17. Liow JS, Lu S, McCarron JA, et al: Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY. Synapse61: 96-105, 2007.
18. Warren KE, Patel MC, McCully CM, et al: Effect of P-glycoprotein modulation with cyclosporine A on cerebrospinal fluid penetration of doxorubicin in non-human primates. Cancer Chemother Pharmacol45: 207-212, 2000.
19. He Q, Gao Y, Zhang L, et al: A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials32: 7711-7720, 2011.
20. Chen YT, Feng B and Chen LB: Update of research on drug resistance in small cell lung cancer chemotherapy. Asian Pac J Cancer Prev13: 3577-3581, 2012.
21. van Vlerken LE, Duan Z, Little SR, et al: Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. AAPS J12: 171-180, 2010.
22. Shin HC, Alani AW, Cho H, et al: A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. Mol Pharm8: 1257-1265, 2011.
23. Nakamura K, Abu Lila AS, Matsunaga M, et al: A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Mol Ther19: 2040-2047, 2011.
24. Batist G, Gelmon KA, Chi KN, et al: Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res15: 692-700, 2009.
25. Wu J, Lu Y, Lee A, et al: Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci10: 350-357, 2007.
26. Qadir M, O'Loughlin KL, Fricke SM, et al: Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res11: 2320-2326, 2005.